Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 4;31(1):1-2.
doi: 10.1016/j.ymthe.2022.12.001. Epub 2022 Dec 16.

First hemophilia B gene therapy approved: More than two decades in the making

Roland W Herzog  1 , Thierry VandenDriessche  2 , Margareth C Ozelo  3
Affiliations
Editorial

First hemophilia B gene therapy approved: More than two decades in the making

Roland W Herzog et al. Mol Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests T.V. received funding from Takeda, Pfizer, and Catalyst Biosciences and speaker honoraria from Takeda, Pfizer, BioMarin, and Biotest; research grants for gene therapy (European Union Horizon 2020 UPGRADE project under grant agreement N°825825 and Vrije Universiteit Brussel – IOF GEAR). M.C.O. received funding from BioMarin, Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda; speaker honoraria from BioMarin, Bayer, Biotest, Pfizer, Roche, and Takeda; and consulting payments from Bayer, BioMarin, Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda. R.W.H. received grant funding from Spark Therapeutics and serves on scientific advisory boards or consultant for Intellia, Regeneron, Pfizer, BioMarin, and Prevail Therapeutics.

References

    1. High K.A., Anguela X.M. Adeno-associated viral vectors for the treatment of hemophilia. Hum. Mol. Genet. 2016;25:R36–R41. doi: 10.1093/hmg/ddv475. - DOI - PMC - PubMed
    1. Samelson-Jones B.J., George L.A. Adeno-associated virus gene therapy for hemophilia. Annu. Rev. Med. 2022;74 doi: 10.1146/annurev-med-043021-033013. - DOI - PMC - PubMed
    1. Samelson-Jones B.J. Worldwide use of factor IX Padua for hemophilia B gene therapy. Mol. Ther. 2022;30:2394–2396. doi: 10.1016/j.ymthe.2022.06.002. - DOI - PMC - PubMed
    1. Simioni P., Tormene D., Tognin G., Gavasso S., Bulato C., Iacobelli N.P., Finn J.D., Spiezia L., Radu C., Arruda V.R. X-linked thrombophilia with a mutant factor IX (factor IX Padua) N. Engl. J. Med. 2009;361:1671–1675. doi: 10.1056/NEJMoa0904377. - DOI - PubMed
    1. VandenDriessche T., Pipe S.W., Pierce G.F., Kaczmarek R. First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy. Mol. Ther. 2022;30:3335–3336. doi: 10.1016/j.ymthe.2022.09.020. - DOI - PMC - PubMed

Publication types